23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › LEGEND BIOTECH CORP. › 2023-2024

LEGEND BIOTECH CORP. 2023-2024 Proxy Voting Records

At LEGEND BIOTECH CORP.'s shareholder meeting held September 21, 2023, in the 2023-2024 proxy season, 69 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,536 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To authorize each of the directors and officers of the Company to take any and every action… — the reporting funds and managers cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings. Page generated November 8, 2026.

  • 6Reported items
  • 69Asset managers
  • 1,536Fund votes
  • September 21, 2023Meeting date

Results at a glance

No official results are on file for this meeting: no Form 8-K tally (Item 5.07) from LEGEND BIOTECH CORP. has been matched to it. The figures below are the funds’ own votes from Form N-PX. They are not the meeting result, so they are not used to judge dissent.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025

Explore LEGEND BIOTECH CORP. in the interactive database Compare manager voting policies

How asset managers voted at the LEGEND BIOTECH CORP. 2023-2024 meeting

Each item below shows how the 69 asset managers that disclosed a LEGEND BIOTECH CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of LEGEND BIOTECH CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company's…

Combines 2 wordings of this item as funds reported it.

95% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 68 asset managers voting on “To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company'” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,608,11997,737 00For
T. Rowe Price4,887,8730 00For
Capital Group4,208,9600 00For
Federated Hermes1,893,1960 00For
BlackRock1,732,5320 00For
Vanguard1,169,204453,984 00Mixed
MFS1,513,5900 00For
MATTHEWS INTERNATIONAL FUNDS943,4570 00For
JANUS INVESTMENT FUND829,0980 00For
AllianceBernstein0377,629 00Against
Principal299,01578,302 00Mixed
MERIDIAN FUND INC0348,285 00Against
Artisan343,3690 00For
Jackson National335,4550 00For
AMG FUNDS231,0000 00For
AB DISCOVERY GROWTH FUND, INC.0229,682 00Against
Equitable149,87876,211 00Mixed
EMERGING MARKETS GROWTH FUND INC219,1450 00For
TOUCHSTONE STRATEGIC TRUST201,7500 00For
Invesco0166,046 00Against
Lincoln Financial147,2080 00For
TIAA133,5710 00For
FRANKLIN STRATEGIC SERIES122,0340 00For
State Street99,3190 00For
Voya94,5940 00For

Fund voting reports, all 68 managers: 34,015,966 for, 1,948,430 against, 8,225 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To re-elect Dr. Corazon D. Sanders, whose term of office will expire pursuant to article 88(b) of the Company'” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC684,7282,675 00For

Institutional-manager reports, all 1 managers: 684,728 for, 2,675 against.

2. To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of…

Combines 2 wordings of this item as funds reported it.

98% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 68 asset managers voting on “To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company's memorandum” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,693,05612,800 00For
T. Rowe Price4,887,8730 00For
Capital Group4,208,9600 00For
Federated Hermes1,893,1960 00For
BlackRock1,732,5320 00For
Vanguard1,623,1880 00For
MFS1,513,5900 00For
MATTHEWS INTERNATIONAL FUNDS943,4570 00For
JANUS INVESTMENT FUND829,0980 00For
AllianceBernstein0377,629 00Against
Principal299,01578,302 00Mixed
MERIDIAN FUND INC348,2850 00For
Artisan343,3690 00For
Jackson National335,4550 00For
AMG FUNDS231,0000 00For
AB DISCOVERY GROWTH FUND, INC.0229,682 00Against
Equitable149,87876,211 00Mixed
EMERGING MARKETS GROWTH FUND INC219,1450 00For
TOUCHSTONE STRATEGIC TRUST201,7500 00For
Invesco166,0460 00For
Lincoln Financial147,2080 00For
TIAA133,5710 00For
FRANKLIN STRATEGIC SERIES122,0340 00For
State Street99,3190 00For
Voya94,5940 00For

Fund voting reports, all 68 managers: 35,189,772 for, 774,624 against, 8,225 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To re-elect Dr. Li Mao, whose term of office will expire pursuant to article 88(b) of the Company's memorandum” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC684,7282,675 00For

Institutional-manager reports, all 1 managers: 684,728 for, 2,675 against.

3. To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of…

Combines 2 wordings of this item as funds reported it.

99.8% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company's memorandum of association, to serve as a Class III director of the Company for a full term of three (3) years.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 68 asset managers voting on “To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company's memorandum” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,705,8560 00For
T. Rowe Price4,887,8730 00For
Capital Group4,208,9600 00For
Federated Hermes1,893,1960 00For
BlackRock1,732,5320 00For
Vanguard1,623,1880 00For
MFS1,513,5900 00For
MATTHEWS INTERNATIONAL FUNDS943,4570 00For
JANUS INVESTMENT FUND829,0980 00For
AllianceBernstein377,6290 00For
Principal377,3170 00For
MERIDIAN FUND INC348,2850 00For
Artisan343,3690 00For
Jackson National335,4550 00For
AMG FUNDS231,0000 00For
AB DISCOVERY GROWTH FUND, INC.229,6820 00For
Equitable226,0890 00For
EMERGING MARKETS GROWTH FUND INC219,1450 00For
TOUCHSTONE STRATEGIC TRUST201,7500 00For
Invesco166,0460 00For
Lincoln Financial147,2080 00For
TIAA133,5710 00For
FRANKLIN STRATEGIC SERIES122,0340 00For
State Street99,3190 00For
Voya94,5940 00For

Fund voting reports, all 68 managers: 35,903,817 for, 60,579 against, 8,225 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To re-elect Dr. Li Zhu, whose term of office will expire pursuant to article 88(b) of the Company's memorandum” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC684,7282,675 00For

Institutional-manager reports, all 1 managers: 684,728 for, 2,675 against.

4. To authorize each of the directors and officers of the Company to take any and every action that might be necessary to…

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: To authorize each of the directors and officers of the Company to take any and every action that might be necessary to effect the foregoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 68 asset managers voting on “To authorize each of the directors and officers of the Company to take any and every action that might be nece” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,705,8560 00For
T. Rowe Price4,887,8730 00For
Capital Group4,208,9600 00For
Federated Hermes1,893,1960 00For
BlackRock1,732,5320 00For
Vanguard1,623,1880 00For
MFS1,513,5900 00For
MATTHEWS INTERNATIONAL FUNDS943,4570 00For
JANUS INVESTMENT FUND829,0980 00For
AllianceBernstein377,6290 00For
Principal377,3170 00For
MERIDIAN FUND INC348,2850 00For
Artisan343,3690 00For
Jackson National335,4550 00For
AMG FUNDS231,0000 00For
AB DISCOVERY GROWTH FUND, INC.229,6820 00For
Equitable226,0890 00For
EMERGING MARKETS GROWTH FUND INC219,1450 00For
TOUCHSTONE STRATEGIC TRUST201,7500 00For
Invesco166,0460 00For
Lincoln Financial147,2080 00For
TIAA133,5710 00For
FRANKLIN STRATEGIC SERIES122,0340 00For
State Street99,3190 00For
Voya94,5940 00For

Fund voting reports, all 68 managers: 35,964,396 for, 8,225 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To authorize each of the directors and officers of the Company to take any and every action that might be nece” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC687,4030 00For

Institutional-manager reports, all 1 managers: 687,403 for.

5. To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2022.

Combines 2 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: votes by 69 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 68 asset managers voting on “To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31,” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,705,8560 00For
T. Rowe Price4,887,8730 00For
Capital Group4,208,9600 00For
Federated Hermes1,893,1960 00For
BlackRock1,732,5320 00For
Vanguard1,623,1880 00For
MFS1,513,5900 00For
MATTHEWS INTERNATIONAL FUNDS943,4570 00For
JANUS INVESTMENT FUND829,0980 00For
AllianceBernstein377,6290 00For
Principal377,3170 00For
MERIDIAN FUND INC348,2850 00For
Artisan343,3690 00For
Jackson National335,4550 00For
AMG FUNDS231,0000 00For
AB DISCOVERY GROWTH FUND, INC.229,6820 00For
Equitable226,0890 00For
EMERGING MARKETS GROWTH FUND INC219,1450 00For
TOUCHSTONE STRATEGIC TRUST201,7500 00For
Invesco166,0460 00For
Lincoln Financial147,2080 00For
TIAA133,5710 00For
FRANKLIN STRATEGIC SERIES122,0340 00For
State Street99,3190 00For
Voya94,5940 00For

Fund voting reports, all 68 managers: 35,964,396 for, 8,225 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To receive the audited consolidated financial statements of the Company for the fiscal year ended December 31,” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC687,4030 00For

Institutional-manager reports, all 1 managers: 687,403 for.

6. To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the "Independent Auditor") for…

Combines 2 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 69 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the "Independent Auditor") for the fiscal year ending December 31, 2023.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 68 asset managers voting on “To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the "Independent Auditor” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity13,705,8560 00For
T. Rowe Price4,887,8730 00For
Capital Group4,208,9600 00For
Federated Hermes1,893,1960 00For
BlackRock1,732,5320 00For
Vanguard1,623,1880 00For
MFS1,513,5900 00For
MATTHEWS INTERNATIONAL FUNDS943,4570 00For
JANUS INVESTMENT FUND829,0980 00For
AllianceBernstein377,6290 00For
Principal377,3170 00For
MERIDIAN FUND INC348,2850 00For
Artisan343,3690 00For
Jackson National335,4550 00For
AMG FUNDS231,0000 00For
AB DISCOVERY GROWTH FUND, INC.229,6820 00For
Equitable226,0890 00For
EMERGING MARKETS GROWTH FUND INC219,1450 00For
TOUCHSTONE STRATEGIC TRUST201,7500 00For
Invesco166,0460 00For
Lincoln Financial147,2080 00For
TIAA133,5710 00For
FRANKLIN STRATEGIC SERIES122,0340 00For
State Street99,3190 00For
Voya94,5940 00For

Fund voting reports, all 68 managers: 35,964,396 for, 8,225 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To ratify the appointment of Ernst & Young LLP as independent auditor of the Company (the "Independent Auditor” at LEGEND BIOTECH CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC687,4030 00For

Institutional-manager reports, all 1 managers: 687,403 for.

Largest LEGEND BIOTECH CORP. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 330,134,480 shares outstanding at the time of that meeting.

Fund voting reports: top LEGEND BIOTECH CORP. shareholders by shares voted on “To authorize each of the directors and officers of the Company to take any and every action…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 4.15%
2T. Rowe Price 1.48%
3Capital Group 1.27%
4Federated Hermes 0.57%
5BlackRock 0.52%
6Vanguard 0.49%
7MFS 0.46%
8MATTHEWS INTERNATIONAL FUNDS 0.29%
9JANUS INVESTMENT FUND 0.25%
10AllianceBernstein 0.11%
Institutional-manager reports: top LEGEND BIOTECH CORP. shareholders by shares voted on “To authorize each of the directors and officers of the Company to take any and every action…”, 2023-2024
#Asset manager % of shares outstanding
1TimesSquare Capital Management, LLC 0.21%

Reported LEGEND BIOTECH CORP. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

LEGEND BIOTECH CORP. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
FMR LLC 12.16% 13G
FMR (Fidelity) 8.39% 13F
T. Rowe Price 3.32% 13F
BlackRock 1.36% 13F
Wellington Management 0.79% 13F
Capital International 0.66% 13F
Citadel Advisors 0.40% 13F
Goldman Sachs 0.36% 13F
State Street 0.32% 13F
Geode Capital 0.14% 13F

Percentages above are of 330,134,480 shares outstanding, as reported by LEGEND BIOTECH CORP. on its Form 20-F dated December 31, 2022 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LEGEND BIOTECH CORP.’s 20-F dated December 31, 2022. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

LEGEND BIOTECH CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Cite this page

proxyvotesnow.com, “LEGEND BIOTECH (LEGN) 2023 Annual Meeting (2023-2024 season)”, https://proxyvotesnow.com/company/legend-biotech-corporation/2024 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.